Navigating the Diagnostic and Clinical Spectrum of Thrombocytopenia and Thrombocytopathy: Lessons from a Case Series

Hannah Glonnegger1, Doris Boeckelmann1, Rebekka Wiedenhoefer1

  • 1Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, Children's Hospital, Faculty of Medicine, Medical Center - University of Freiburg, Freiburg, Germany.

Hamostaseologie
|May 4, 2026
PubMed

BACKGROUND: Despite major advances in platelet function testing and molecular genetic diagnostics, the evaluation of inherited thrombocytopenia and thrombocytopathy remains challenging. Overlapping clinical phenotypes, variants of uncertain significance (VUS), and structural variants detectable only by complementary copy-number variant (CNV) analysis or array comparative genomic hybridization (CGH) frequently impede diagnostic classification.

METHODS: We report seven pediatric patients from five unrelated families, structured into two diagnostic parts. Part 1 addresses inherited platelet disorders evaluated using a standardized diagnostic algorithm including complete blood count, light transmission aggregometry (LTA), flow cytometry (FC)-based platelet phenotyping, and targeted next-generation sequencing (NGS) including CNV analysis. Part 2 focuses on disorders involving the von Willebrand factor (VWF) axis, assessed by the VWF antigen (VWF:Ag), VWF collagen binding activity (VWF:CBA), VWF multimer analysis, ADAMTS13 activity and antigen, LTA, and molecular genetic testing.

RESULTS: Three diagnostically relevant constellations were identified. In Part 1, one patient with a classical Hermansky-Pudlak syndrome phenotype required CNV analysis to detect compound heterozygous pathogenic variants. Two siblings fulfilled diagnostic criteria for Glanzmann thrombasthenia based on LTA, FC, and genetic testing. A third patient showed a Glanzmann-like phenotype in LTA and FC but carried a homozygous VUS in ITGA2B combined with a heterozygous ANKRD26 nonsense mutation. In Part 2, three additional patients demonstrated rare VWF-mediated mechanisms of thrombocytopenia due to ADAMTS13 deficiency or von Willebrand disease type 2B.

CONCLUSIONS: This case series highlights the diagnostic complexity of pediatric platelet disorders and emphasizes the importance of a multimodal approach integrating functional platelet assays, NGS including CNV analysis, and careful clinical correlation.

Related Concept Videos

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
470
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.7K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
438
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
418
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
773
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
7.2K